MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy
References (18)
- et al.
Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis
Brain Research
(1990) - et al.
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Pain
(1988) Excitatory transmission in the dorsal horn is in part mediated through APV-sensitive NMDA receptors
Neurosci. Lett.
(1989)- et al.
First-order nociceptive synapses in rat dorsal horn are blocked by an amino acid antagonist
Brain Research
(1986) - et al.
Strychine-enhanced transsynaptic degeneration of dorsal horn neurons in rats with an experimental painful neuropathy
Neurosci. Lett.
(1989) - et al.
Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic construction injury, transection, and strychnine
Pain
(1990) - et al.
Analysis of 125-I-substance P binding sites in rat spinal cord in an experimental model of peripheral neuropathy
Soc. Neurosci. Abstr.
(1989) - et al.
Neurochemical and anatomical changes in the dorsal horn of rats with an experimental painful peripheral neuropathy
- et al.
An experimental peripheral neuropathy in rat that produces abnormal pain sensation
Cited by (257)
IUPHAR review: Navigating the role of preclinical models in pain research
2024, Pharmacological ResearchTherapeutic potential of agmatine for CNS disorders
2017, Neurochemistry InternationalSource memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors
2016, Behavioural Brain ResearchThe transition from naïve to primed nociceptive state: A novel wind-up protocol in mice
2016, Experimental NeurologyMemantine, a promising drug for the prevention of neuropathic pain in rat
2013, European Journal of PharmacologyCitation Excerpt :In animal, NMDA receptor antagonists show controversial results. Neuropathic pain symptoms are decreased after treatment with MK801 (Davar et al., 1991; Mao et al., 1992, Smith et al., 1994), ketamine (Mao et al., 1993), dextromethorphan (Mao et al., 1993) or unchanged with MK801 (Wegert et al. 1997) and dextromethorphan (Tal and Bennett, 1994). These drugs may however have severe side-effects limiting their clinical use (Cvrcek, 2008).
This work was supported by a National Research Service Award (NINDS Grant IF32NS085 34-02).
- *
The authors wish to acknowledge the support of Miriam Chernoff and Lee Baer of the Biostatistics Division at the Massachussetts General Hospital, and the support and encouragement of gary J. Bennett at the National Institutes of Dental Research, NIH.